Brief: Chimerix Announces Successful Launch Of ONC201 Phase 3 Study At Society For Neuro-Oncology Conference And Provides Operational Update

Chimerix

08/12/2022 22:09

Dec 8 (Reuters) - Chimerix Inc  CMRX.O :
    * CHIMERIX ANNOUNCES SUCCESSFUL LAUNCH OF ONC201 PHASE 3
ACTION
STUDY AT SOCIETY FOR NEURO-ONCOLOGY CONFERENCE AND PROVIDES
OPERATIONAL UPDATE
    * CHIMERIX INC - TO FOCUS ON PHASE 3 ACTION STUDY AS
POTENTIAL
FIRST APPROVAL FOR ONC201 FOLLOWING INTERACTIONS WITH U.S. FDA
    * CHIMERIX - FOLLOWING TEMBEXA TRANSITION, PLANNED WORKFORCE
REDUCTION OF ABOUT 25%
    * CHIMERIX INC - COMPANY TO FOCUS ON PHASE 3 ACTION STUDY AS
POTENTIAL FIRST APPROVAL FOR ONC201 FOLLOWING INTERACTIONS WITH
FDA
    * CHIMERIX - DATA SUPPORT A POTENTIALLY MEANINGFUL OVERALL
SURVIVAL (OS) ADVANTAGE FOR ONC201 IN RECURRENT SETTING

Source text for Eikon:  ID:nGNX66kC0J 
Further company coverage:  CMRX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))